(NASDAQ: ONCY) Clinical-Stage Immunotherapy With 7 Catalysts And A $6.00 Zacks Price Target
June 23, 2026 educational breakdown — Oncolytics Biotech's pelareorep is delivering 2-3x efficacy over standard of care in GI cancers (REO 022 data released May 4, 2026), a Type C FDA meeting on a single-arm pivotal in anal cancer is complete,. Stock trades near $0.80 against a 6-analyst consensus of $5.02 (Strong Buy) and a Zacks $6.00 PT.
June 2026 Oncolytics Biotech Investor Presentation (PDF)
Oncolytics Biotech Inc.
NASDAQ: ONCY
Last updated: 7/15/2026, 7:58:36 AM. Educational only.
Why This Setup Is On Our Radar
A validated immunotherapy platform with three focused GI cancer programs, near-term regulatory catalysts, and a fully funded pipeline — trading near $0.80 against a 6-analyst consensus target of $5.02.
Get the Full ONCY Breakdown + Future Alerts
Educational email & SMS updates on Oncolytics Biotech (NASDAQ: ONCY) and other setups we are watching.
By submitting you agree to receive recurring educational emails & SMS. Msg & data rates may apply. Reply STOP to cancel. Not investment advice.
Oncolytics Biotech Inc. (NASDAQ: ONCY)
June 23, 2026
A clinical-stage immunotherapy company just released data the market hasn't properly priced in, and the setup is getting harder to ignore.
The company's lead asset, pelareorep, is delivering 2-3x improvements over standard-of-care benchmarks in multiple difficult-to-treat GI cancers — including data that would support accelerated approval pathways in the near term.
Add a completed Type C FDA meeting, a validated mechanism that works across multiple cancer types, and a strategy narrowing toward the highest-probability indications, and you'll see why this profile climbed to the top of our watchlist.
This is the setup we are watching.
Company Overview
Oncolytics Biotech is a clinical-stage immunotherapy company developing pelareorep, an investigational treatment that replicates inside tumor cells carrying RAS-pathway mutations while converting immunologically "cold" tumors into "hot" tumors the immune system can attack.
The company recently completed a change in jurisdiction of incorporation to Nevada and relocated its headquarters to San Diego — positioning for more efficient capital-markets access. Leadership has been strengthened with executives in strategy, operations, and biostatistics.
Pelareorep is being advanced in combination with standard chemotherapy across three GI cancer types where few treatment options exist and patient populations are large: 2L mCRC, ≥2L SCAC, and 1L mPDAC.
Mechanism — Converting Cold Tumors to Hot
Pelareorep is a non-genetically modified virus that selectively targets cancer cells with RAS mutations while leaving healthy cells alone. When it replicates inside a tumor, it triggers an immune response that wakes up the body's defenses against the cancer.
- 1Pela is injected intravenously and travels to tumors, evading neutralization by associating with mononuclear cells in the blood.
- 2It selectively infects and replicates inside cancer cells with RAS-pathway mutations, producing dsRNA inside the tumor.
- 3Some tumor cells are killed directly; the infection releases danger signals (chemokines, cytokines, type I IFN) — turning a cold tumor hot.
- 4Activated tumor-infiltrating lymphocyte clones expand and attack the tumor; tertiary lymph nodes form within the tumor microenvironment.
Source: Oncolytics Biotech June 2026 Investor Presentation — download PDF
Pipeline & Clinical Data
Pelareorep Platform
Non-genetically modified reovirus, IV-delivered, selectively replicating in RAS-pathway tumor cells. dsRNA activates innate and adaptive immune responses — converting cold tumors to hot. >1,200 patients treated across 20+ studies.
2L mCRC — REO 022 (May 4, 2026)
Pela + FOLFIRI + bevacizumab in KRAS-mutant MSS 2L mCRC: 19.5-month median DoR vs. 4-6 months historical, 33% ORR vs. 6-11% SoC, 27-month OS vs. 11.2 months, 16.6-month PFS vs. 5.7 months. Fast Track designation; randomized Phase 2 enrolling.
Anal Cancer — SCAC, GOBLET Cohort 4
30% ORR vs. 10-14% real-world; 17-month median DoR; 2 complete remissions with one ongoing past 28 months. Type C FDA meeting (April 6, 2026) aligned a single-arm pivotal (~60-70 patients); Q3 2026 launch; potential BLA 2028.
1L Pancreatic — REO 017 / NCI 8601 / REO 029
Pela + gemcitabine: 24% 2-yr survival vs. 4% (6x); randomized controlled study: 20% 2-yr vs. 6%; REO 029 Cohort 5 (pela + mFOLFIRINOX +/- atezo): 62% response rate vs. 23% chemo alone. Readout H2 2026. FDA Fast Track + Orphan Drug.
Why ONCY Is On Our Radar
The clinical activity does not match the price. Pelareorep is generating 2-3x signals over standard of care across multiple GI cancers while the stock trades near $0.80 — versus a 6-analyst consensus target of $5.02 and a Zacks $6.00 PT.
- 2-3x efficacy signals over standard of care across three GI indications
- Type C FDA meeting completed; single-arm pivotal SCAC design aligned
- FDA Fast Track in colorectal and pancreatic; Orphan Drug in pancreatic
- TradingView 6-analyst consensus $5.02 (Strong Buy, range $2.92–$9.90); Zacks $6.00
- Fully funded pipeline across three substantial GI cancer markets
Leadership Team
Substantial expertise across immuno-oncology, clinical development, business development, manufacturing, and finance.
Source: Oncolytics Biotech June 2026 Investor Presentation — download PDF
Seven Catalysts to Watch
REO 022 Data in 2L Metastatic Colorectal Cancer
The May 4, 2026 release — 19.5-mo DoR, 33% ORR, 27-mo OS, 16.6-mo PFS — is the strongest clinical signal in the company's history. A randomized Phase 2 is enrolling, and the company is engaging FDA on accelerated approval.
Type C FDA Meeting → Single-Arm SCAC Pivotal
April 2026 Type C meeting aligned the SCAC single-arm pivotal design — a regulatory de-risking event. Study launch expected Q3 2026, with potential BLA filing as early as 2028.
FDA Fast Track in Colorectal & Pancreatic
Fast Track enables more frequent FDA meetings, rolling NDA/BLA review, and potential priority review — compressing timelines and reducing development risk across both programs.
REO 029 Cohort 5 Readout (H2 2026)
Pela + modified FOLFIRINOX +/- atezolizumab — the most aggressive backbone tested — completed enrollment. Data are expected H2 2026 and may inform pivotal Phase 3 design. Partnership announcements could occur concurrently.
Strategic Partnership Announcements
Active partnering discussions with major pharma. A pancreatic partnership would be transformational — funding a large pivotal study and commercial execution. Watch the next 6-12 months.
Analyst Initiation & Coverage Expansion
Zacks Small Cap Research initiated April 6, 2026 at $6.00. TradingView 6-analyst consensus is $5.02 (range $2.92–$9.90, Strong Buy). Broader sell-side coverage could follow as the colorectal durability data and SCAC pivotal gain visibility.
Manufacturing Scale-Up (Carlsbad, CA)
Pelareorep is produced in Carlsbad, CA via a high-yield, low-cost process. Scale-up and supply-chain validation are key de-risking milestones ahead of potential commercial launch.
Market Opportunity
Three large GI cancer indications with very few effective options — all addressed by a single validated mechanism.
2L Metastatic Colorectal Cancer
RAS-mutant population with high unmet medical need
≥2L Squamous Cell Anal Carcinoma (SCAC)
Evolving SoC with very few treatment options
1L Metastatic Pancreatic (mPDAC)
Chemo SoC with no approved immunotherapy
The Platform Advantage
Pelareorep is a validated platform immunotherapy. Cold-to-hot conversion has been documented in biopsies across multiple cancer types, with more than a decade of clinical experience and 1,200+ patients treated across 20+ studies.
Manufacturing is run from Carlsbad, California using a high-yield, low-cost process — de-risking commercial scale-up. The three-indication strategy spans the full regulatory spectrum: single-arm registration in SCAC, randomized Phase 2 in 2L mCRC, and partnership-driven Phase 3 in 1L pancreatic.
The pipeline is fully funded across all three indications, giving management runway to execute on near-term catalysts without dilution-driven pressure.
Short-Term View
REO 022 durability data in 2L mCRC, Type C alignment on a single-arm SCAC pivotal, Fast Track designations, and a wide gap between the $5.02 analyst consensus (Strong Buy) and a stock near $0.80.
Long-Term View
A validated platform immunotherapy advancing across three GI cancers, with potential first registration in SCAC as early as 2028-2029 and partnership-driven expansion into the larger colorectal and pancreatic markets.
Check Your Brokerage For The Latest On ONCY
Brokerage names are property of their respective owners. Listed for convenience only — no affiliation or endorsement implied.
Add Oncolytics Biotech Inc. (NASDAQ: ONCY) to Your Watchlist
Get our full educational breakdown on this clinical-stage immunotherapy - including the pelareorep clinical data and all 7 catalysts - plus future alerts on setups like this.
MASTER LEGAL DISCLAIMER
Last Updated: July 12, 2026
Publisher: Relqo Media LLC (Wyoming, United States)
Subject Company: Oncolytics Biotech Inc. (ONCY)
IMPORTANT SUMMARY — PLEASE READ FIRST
This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Oncolytics Biotech Inc. to produce and distribute promotional content regarding Oncolytics Biotech Inc. (NASDAQ: ONCY). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.
1. NATURE AND INTENT OF THIS COMMUNICATION
Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company’s operations or investment merit.
2. COMPENSATION FOR Oncolytics Biotech Inc. (ONCY)
Relqo Media LLC has received cash compensation for the publication, distribution, and dissemination of investor awareness and promotional materials relating to Oncolytics Biotech Inc. (NASDAQ: ONCY).
Relqo Media LLC has received forty thousand dollars ($40,000) for promotional services to be rendered during a five-day campaign commencing on July 13, 2026 and concluding on July 17, 2026. The compensation was paid directly by Oncolytics Biotech Inc., the issuer.
Relqo Media LLC previously received fifty thousand dollars ($50,000) for promotional services rendered during a five-day campaign commencing on June 15, 2026 and concluding on June 20, 2026. The compensation was paid directly by Oncolytics Biotech Inc., the issuer.
The aggregate cash compensation received by Relqo Media LLC in connection with these promotional and investor awareness campaigns relating to Oncolytics Biotech Inc. is ninety thousand dollars ($90,000).
This compensation arrangement creates a direct, material, and unavoidable conflict of interest.
As a result of the compensation described above, all materials, publications, communications, opinions, and content disseminated by Relqo Media LLC concerning Oncolytics Biotech Inc. must be considered paid promotional content and not independent, objective, or unbiased analysis.
Relqo Media LLC is not a registered broker-dealer, investment adviser, or securities analyst, and is not acting in any such capacity. Nothing disseminated by Relqo Media LLC constitutes investment advice, an offer to sell, or a solicitation of an offer to buy any securities. Recipients should conduct their own independent due diligence and consult with licensed financial and legal professionals before making any investment decisions.
Neither Relqo Media LLC nor Oncolytics Biotech Inc. makes any representation, warranty, or guarantee regarding the accuracy, completeness, or timeliness of the information disseminated, and each expressly disclaims any liability for losses that may arise from reliance on such promotional materials.
Relqo Media LLC, its officers, members, affiliates, contractors, and related parties do not own any shares of Oncolytics Biotech Inc. (NASDAQ: ONCY) as of the date of publication of this disclaimer
3. INTENDED AUDIENCE
These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.
4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS
Relqo Media LLC does not, and has not, independently verified, investigated, audited, or substantiated any statements, representations, or claims made by the featured company, its officers, directors, employees, affiliates, agents, press releases, marketing materials, or any third-party sources.
Any and all information regarding Oncolytics Biotech Inc. (NASDAQ: ONCY)—including but not limited to business descriptions, operational updates, clinical trial progress, scientific data, partnerships, revenue projections, market opportunity estimates, or strategic plans—should be assumed to be unverified, unaudited, incomplete, potentially inaccurate, and subject to change without notice.
We make no warranties or representations as to the truthfulness, accuracy, reliability, or completeness of such information, and you should not interpret our publication of these statements as an endorsement or confirmation of their validity.
You should not rely on any company-provided claims, projections, or forward-looking statements for the purpose of making an investment decision. All such statements may be speculative, overstated, selectively presented, or based on assumptions that may never materialize.
If you choose to invest, you do so entirely at your own risk, and you should conduct thorough, independent due diligence—including reviewing SEC filings, consulting licensed investment professionals, and obtaining independent verification of any material facts—before making any investment decision.
5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION
Historically, promotional campaigns for microcap and small-cap securities—particularly those driven by paid advertising—often cause temporary, artificial, and unsustainable increases in share price and trading volume. These movements are typically fueled by short-term speculative interest, promotional circulation, algorithmic trading activity, and momentum-based retail buying rather than any change in the underlying business, operations, or financial condition of the company.
You should assume and expect that:
- ONCY’s share price may experience sharp, rapid, and potentially extreme increases during the period of active promotion;
- Trading volume may spike dramatically due to speculative buying pressure, news catalysts amplified by promotional activity, and social media or online forum chatter;
- Once buying interest subsides, selling begins, or the promotion ends—which may occur suddenly and without notice—the share price may decline precipitously, potentially returning to pre-promotion levels or lower, often within days or even hours; and
- These price and volume movements are not reflective of intrinsic value and may have no correlation to the company’s actual fundamentals or long-term business prospects.
Past market behavior shows that such promotional price spikes are frequently followed by steep losses, which can be rapid and irreversible. If you purchase shares during or shortly after a promotional period, you should be prepared for the high probability of losing a substantial portion, or all, of your investment.
By engaging with our content, you acknowledge and agree that you fully understand the speculative, volatile, and high-risk nature of securities subject to promotional activity, and you will not hold Relqo Media LLC responsible for any losses resulting from such trading patterns.
6. NO RELIANCE – INVESTOR RESPONSIBILITY
The burden of research, verification, and risk assessment rests entirely with you, the reader. All content produced and distributed by Relqo Media LLC is promotional in nature and should not be the basis for any investment decision. We are not responsible for your interpretation or use of the information contained herein.
You are solely responsible for:
- Reviewing and analyzing all publicly available information, including but not limited to SEC filings, audited financial statements, and official company disclosures;
- Consulting with a licensed, qualified investment professional, attorney, or tax adviser before making any investment decision;
- Understanding and accepting the risks inherent in microcap and early-stage public companies, which may include extreme volatility, illiquidity, lack of financial transparency, insider selling, share dilution, regulatory challenges, and business failure.
We make no warranties or representations as to the accuracy, completeness, timeliness, or reliability of any information presented. Any data, figures, or statements regarding the featured company’s business, market opportunity, future performance, or partnerships may be incomplete, outdated, or incorrect. You should assume that certain information is based on third-party sources we have not independently verified.
By viewing our materials, you agree that:
- You will not rely solely on our communications in making an investment decision;
- You accept full responsibility for conducting independent due diligence; and
- Relqo Media LLC and its affiliates will not be liable for any losses or damages arising from your reliance on our content.
7. FORWARD-LOOKING STATEMENTS, ASSUMPTIONS, AND ACCURACY NOTICE
Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as well as other predictive or aspirational language regarding future events, performance, or results. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “may,” “will,” “should,” “could,” “projects,” “estimates,” “potential,” and similar expressions are intended to identify such statements. These statements are inherently uncertain, based on current expectations, estimates, and assumptions that may prove to be incorrect, incomplete, or no longer applicable at the time you read them.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to: changes in market conditions, regulatory decisions, the outcome of clinical trials, competitive pressures, the availability of financing, and broader economic or geopolitical developments.
Additionally, some information presented in our content is derived from third-party sources, company press releases, or statements from officers, directors, or affiliates of the featured company. We do not independently verify or guarantee the accuracy, completeness, or timeliness of such information. Any claim, projection, or forward-looking statement should be considered purely speculative and potentially outdated..
You should not place undue reliance on forward-looking statements or assume that they will prove to be accurate. Relqo Media LLC undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, changes in circumstances, or the emergence of new information, except as required by law.
8. INFORMATION SOURCING, BIAS, AND ACCURACY
We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.
Assume all information presented by Relqo Media is:
- Subjective,
- Not independently verified,
- Created to highlight potential upside and omit downsides,
- Not suitable as the basis for any investment decision.
9. OWNERSHIP AND TRADING CONFLICTS
Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including ONCY. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.
10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT
We use a range of outreach and promotional tools, including:
- Email and newsletter distributions,
- SMS/MMS text campaigns,
- Social media posts and influencers,
- Google and native display ads,
- Press releases, video marketing, and paid content distribution.
By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.
11. ADVERTISING LAW COMPLIANCE
Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.
We make good-faith efforts to disclose all:
- Compensation arrangements,
- Conflicts of interest,
- Risks,
- Limitations of our role, and
- The promotional nature of this content.
We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.
12. NON-U.S. USERS
This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.
13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY
All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:
- Investment losses,
- Inaccuracies,
- Technical delays,
- User misunderstandings,
- Omissions or errors in content.
Total liability for any claim shall not exceed one hundred dollars ($100).
14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION
All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.
15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS
Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.
16. FINAL NOTICE – ACCEPTANCE OF TERMS
We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.
If you do not accept all terms of this disclaimer in full, you must:
- Exit our websites,
- Unsubscribe from our communications,
- Discontinue viewing all Relqo Media promotional content.
17. NO RELIANCE
By viewing or engaging with this content, you agree that:
- You will not rely on any statements made by Relqo Media for investment purposes,
- You waive any claim that our content was a material factor in your investment decision,
- You have read, understood, and accepted this disclaimer in full.
© 2024 Relqo Media LLC. All Rights Reserved.
Legal Contact: 📧 support@topstocks.com
Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801
Affiliate Disclosure: Relqo Media LLC owns and operates TopStocks.com and all affiliated digital properties.